Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 5, 2024; 15(6): 98146
Published online Nov 5, 2024. doi: 10.4292/wjgpt.v15.i6.98146
Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials
Naveen Jeyaraman, Madhan Jeyaraman, Tejaswin Mariappan, Sathish Muthu, Swaminathan Ramasubramanian, Shilpa Sharma, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana
Naveen Jeyaraman, Madhan Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India
Naveen Jeyaraman, Madhan Jeyaraman, Sathish Muthu, Department of Research Methods, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India
Madhan Jeyaraman, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana, Department of Orthopaedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil
Tejaswin Mariappan, Department of Community Medicine, Government Stanley Medical College and Hospital, Chennai 600001, Tamil Nadu, India
Sathish Muthu, Department of Orthopaedics, Government Medical College, Karur 639004, Tamil Nadu, India
Sathish Muthu, Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India
Swaminathan Ramasubramanian, Department of Orthopaedics, Government Medical College, Omandurar Government Estate, Chennai 600002, Tamil Nadu, India
Shilpa Sharma, Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi 110029, India
Co-first authors: Naveen Jeyaraman and Madhan Jeyaraman.
Author contributions: Jeyaraman M, Mariappan T, and Jeyaraman N contributed to conceptualization; Mariappan T and Ramasubramanian S contributed to acquiring the clinical data and performing the data analysis; Jeyaraman M, Mariappan T, and Ramasubramanian S contributed to manuscript writing; Jeyaraman M, Santos GS, Fonseca LF, and Lana JF helped in manuscript revision; Muthu S contributed to image acquisition; Jeyaraman M contributed to proofreading; Jeyaraman M and Lana JF contributed to administration. All authors have agreed to the final version to be published and agree to be accountable for all aspects of the work.
Conflict-of-interest statement: The authors declare no conflict of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com
Received: June 18, 2024
Revised: August 6, 2024
Accepted: September 10, 2024
Published online: November 5, 2024
Processing time: 128 Days and 4.7 Hours
Abstract

With the rising prevalence of chronic liver diseases worldwide, there exists a need to diversify our artillery to incorporate a plethora of diagnostic and therapeutic methods to combat this disease. Currently, the most common causes of liver disease are non-alcoholic fatty liver disease, hepatitis, and alcoholic liver disease. Some of these chronic diseases have the potential to transform into hepatocellular carcinoma with advancing fibrosis. In this review, we analyse the relationship between the gut and liver and their significance in liver disease. This two-way relationship has interesting effects on each other in liver diseases. The gut microbiota, through its metabolites, influences the metabolism in numerous ways. Careful manipulation of its composition can lead to the discovery of numerous therapeutic potentials that can be applied in the treatment of various liver diseases. Numerous cohort studies with a pan-omics approach are required to understand the association between the gut microbiome and hepatic disease progression through which we can identify effective ways to deal with this issue.

Keywords: Gut-liver axis; Dysbiosis; Liver disease; Probiotics; Fecal microbiota transplantation; Precision medicine

Core Tip: We explore the bidirectional impact of gut-liver interactions on liver disease, highlighting how gut microbiota metabolites affect metabolism. It suggests that altering gut microbiota composition could unveil new treatments for liver ailments. Future cohort studies using pan-omics will be crucial in understanding gut microbiome links to liver disease progression and finding effective interventions.